综述:腹泻型肠易激综合征(IBS-D)与混合型肠易激综合征(IBS-M)当前及未来的治疗方法
本文综述了IBS-D和IBS-M的非药物与药物治疗证据,检索Medline和Embase至2021年4月30日。饮食调整常为一线治疗,心理治疗获强证据支持,药物包括止泻药、解痉药、抗抑郁药、胆汁酸吸收不良治疗及美国FDA批准的利福昔明、艾沙多林和阿洛司琼。未来疗法可能包括粪菌移植、Crofelemer和5-羟色胺拮抗剂,但需进一步研究。
要点
- 饮食调整常为IBS-D和IBS-M的一线治疗。
- 心理治疗在IBS治疗中获强证据支持。
- FDA批准药物包括利福昔明、艾沙多林和阿洛司琼。
核心结论
- IBS-D和IBS-M的治疗理想上涉及初级保健、消化科医生和心理学家的多学科方法。
- 治疗常包括非药物和药物疗法。
- 未来疗法可能包括粪菌移植、Crofelemer和5-羟色胺拮抗剂,但需进一步研究。
研究设计与样本
- 综述文章,检索Medline和Embase数据库至2021年4月30日,纳入IBS-D受试者的临床研究,涉及饮食调整、替代治疗(益生菌、针灸、运动)及FDA批准药物。
主要发现
- 饮食调整常为一线治疗。
- 生活方式治疗包括补充替代药物(CAM)、益生菌和薄荷油是有用的辅助手段,但未在IBS-D/IBS-M中专门描述。
- 证据强烈支持心理治疗用于IBS治疗。
- 药物治疗除非处方止泻药、解痉药和抗抑郁药外,还包括胆汁酸吸收不良治疗及FDA批准的利福昔明、艾沙多林和阿洛司琼。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Irritable bowel syndrome-diarrhoea (IBS-D) and IBS-mixed stool pattern (IBS-M) are disorders of gut-brain interaction characterised by abdominal pain associated with diarrhoea or both diarrhoea and constipation respectively. The pathophysiology of IBS-D/M is multifactorial and not completely understood; thus, treatment is aimed at multiple mechanisms such as altering gut microbiota, visceral hypersensitivity, intestinal permeability, gut-brain interaction and psychological strategies. AIM: The goal of this article was to provide an up-to-date review of the current evidence for both non-pharmacological and pharmacological treatment options in IBS-D and IBS-M. Future treatments for IBS-D and IBS-M will also be discussed. METHODS: Medline and Embase database searches (through April 30 2021) to identify clinical studies in subjects with IBS-D in which dietary modification, alternative treatments (probiotics, acupuncture, exercise) as well as FDA-approved medications were used. RESULTS: Dietary modification is often the first line of therapy. Furthermore, lifestyle treatments include complementary alternative medications (CAM), probiotics and peppermint oil are useful adjuncts but have not specifically been described in IBS-D/M. Evidence strongly supports psychotherapy in the treatment of IBS. Beyond over-the counter anti-diarrhoeals, anti-spasmodics and anti-depressants, pharmacological treatment now includes treating for bile acid malabsorption and the FDA-approved medications rifaximin, eluxadoline and alosetron. CONCLUSIONS: The treatment of IBS-D/M ideally involves a multidisciplinary approach of primary care, gastroenterologist and psychologist. Treatment often involves both non-pharmacological and pharmacological therapies. Future therapies may include faecal microbial transplant, Crofelemer and serotonin antagonists, but further studies are needed.
引用
- Nee J, Lembo A. Review Article: Current and future treatment approaches for IBS with diarrhoea (IBS-D) and IBS mixed pattern (IBS-M). Aliment Pharmacol Ther. 2021. PMID: 34927757. doi:10.1111/apt.16625
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。